Acadia Pharmaceuticals Inc. Securities Litigation (2021)

Filing Deadline: June 18, 2021

If you purchased a significant amount of shares of ACADIA Pharmaceuticals Inc. Common Stock (NASDAQ: ACAD), you have certain options. Investors should contact us before June 18, 2021.

 

Lawsuit Overview

Defendant:ACADIA Pharmaceuticals Inc. Common Stock
Date Filed:April 19th, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:June 15th, 2020
Class End Date:April 4th, 2021

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for ACADIA Pharmaceuticals Inc. Common Stock

 
First Identified Complaint

Denise Marechal, et al. v. Acadia Pharmaceuticals Inc., et al.

Date Filed:April 19th, 2021
Class Period Start:June 15th, 2020
Class Period End:April 4th, 2021
First Identified Complaint Filings
#Document TitleFiling Date